

## CLAIMS

1. A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the Polymorph) characterised in that it provides:
- (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709  $\text{cm}^{-1}$ ; and/or
  - (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888  $\text{cm}^{-1}$ ; and/or
  - (iii) a solid-state  $^{13}\text{C}$  nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or
  - (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms
2. A Polymorph according to claim 1, which provides an infra red spectrum substantially in accordance with Figure I.
3. A Polymorph according to claim 1 or claim 2, which provides provides a Raman spectrum substantially in accordance with Figure II.
4. A Polymorph according to any one of claims 1 to 3, which provides provides a solid-state  $^{13}\text{C}$  nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.
5. A Polymorph according to any one of claims 1 to 3, which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.
6. A Polymorph according to any one of claims 1 to 5, in isolated form.
7. A Polymorph according to any one of claims 1 to 6, in pure form.
8. A Polymorph according to any one of claims 1 to 7, in crystalline form.
9. A process for preparing a Polymorph according to claim 1, characterised in that either:
- (a) Compound (I) is suspended in acetone and stirred at an elevated temperature for an extended period of time; or

(b) Compound (I) in denatured ethanol at an elevated temperature is seeded with crystals of the Polymorph, the reaction mixture is then cooled so as to provide the Polymorph;  
after which time the Polymorph is recovered from the denatured ethanol.

5

10. A pharmaceutical composition comprising an effective, non-toxic amount of a Polymorph according to claim 1 and a pharmaceutically acceptable carrier therefor.

11. A Polymorph according to claim 1, for use as an active therapeutic substance.

10

12. A Polymorph according to claim 1, for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

15

13. The use of Polymorph for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

14. A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph to a human or non-human mammal in need thereof.